You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Safe And Effective Anti-CD154 Antibodies For Therapeutic Intervention
SBC: Immunext, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): There is compelling evidence that ?CD154 treatment has great potential in autoimmunity and graft rejection. Autoimmunity. Clinical efficacy of ?CD154 treatment has been seen in Lupus and idiopathic thrombocytopenia. In addition, Principal Investigator Dr. Noelle's clinical experience with ?CD154 is based on a Phase I trial in remitting/ relapsi ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Biomarker discovery for immunodiagnosis of invasive candidiasis
SBC: DXDISCOVERY INC Topic: NIAIDDESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Combination immunotherapies for the treatment of melanoma
SBC: CELDARA MEDICAL, LLC Topic: NCIDESCRIPTION (provided by applicant): Melanoma is the most common form of cancer in young adults1, and its incidence is rising at a rate higher than any of the seven most common cancers2, increasing 45% between 1992 and 20043. Plexxikon and Roche are codeveloping a BrafV600E inhibitor (i.e. PLX4032 (Vemurafenib)) and BMS/Medarex recently attained FDA approval for their anti-CTLA4 antibody (i.e. ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Wireless and Noise Attenuating Headset for Automated Hearing Screening
SBC: CREARE LLC Topic: NIDCDDESCRIPTION (provided by applicant): Hearing loss is a leading public health concern, with about 17% of American adults reporting some degree of impairment. Of those, fewer than 20% seek help for their condition for a variety of reasons. To address this issue, the National Institue of Deafness and Other Communication Disorders (NIDCD) is seeking solutions to improve hearing healthcare access and l ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
An Automated Platform for High-throughput Network Electrophysiology
SBC: CALISTA THERAPEUTICS INC Topic: NHLBIDESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Developing an Improved Electrocompetent E. coli Host
SBC: Pro-Change Behavior Systems, Inc. Topic: NCATSDESCRIPTION (provided by applicant): Chronic musculoskeletal pain creates a significant public health burden. Veterans are disproportionately affected by chronic musculoskeletal pain, and in particular, chronic low back pain (CLBP). The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), and all three conditions (Post-deployment Multi-symptom Disorder (PM ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Chloroquine Sensitive Plasmodium falciparum for MultiValent Vaccine and Challenge
SBC: Simbex LLC Topic: NINRDESCRIPTION (provided by applicant): The Principal Objective of this Fast Track SBIR project is to develop and validate a cost-effective commercial product, TheraSense , a highly innovative active support surface bed system for the treatment and prevention of serious decubitus ulcers, commonly known as bed sores or pressure ulcers. Current advanced bed systems for both institutional and home ther ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Adherence Monitoring for Substance Abuse Clinical Trials
SBC: CREARE LLC Topic: NIDADESCRIPTION (provided by applicant): The evaluation and selection of safe and effective pharmacotherapies for drug abuse and addiction, as well as many other diseases and disorders, is performed through clinical trials that rely on patients taking the studied medication at the specified time and frequency. To ensure accurate efficacy measures, adherence to the prescribed regimen must be known. Cr ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Advanced training platform and methodologies for emergency responders and skilled
SBC: Nicolalde R&D LLC Topic: NIEHSDESCRIPTION (provided by applicant): There is a need to be able to deliver just-in-time training and reference materials for first responders and skilled support personnel. Mobile computing platforms are becoming ubiquitous and provide an ideal means to reach users at any time in any location. The process of translating existing reference materials into mobile-friendly formats is currently manual ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Expediting the Production of High Value, Standardized, and Transparent Data
SBC: MJ Datacorp, Ltd. Topic: NCATSDESCRIPTION (provided by applicant): Researchers and contractors are under increasing pressure to produce rapid turnaround times for data releases and publications. Inadequate data management is a common threat to good research and impedes the quick release of high value data. Despite its importance, many organizations do not have standardized data management practices that allow them to prepare h ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health